

3RD APHOG Annual Meeting 2024

Abstract Booklet



APHOG

Annual Meeting

2024

**16th Congress of Asia continental branch of
International Society of Pediatric Oncology**

APHOG Annual Meeting 2024

Welcome Message



On behalf of all the members of Asian Pediatric Hematology and Oncology Group (APHOG), I would like to congratulate a successful meeting of the SIOP Asia 2024 held in Yokohama on June 21–25, 2024, that is actually the first SIOP Asia congress in Japan. We would also like to express sincere thanks to Dr. Kimikazu Matsumoto, chairman of the SIOP Asia 2024, for kindly accepting to have the 3rd APHOG Annual Meeting 2024 together.

APHOG was officially founded in March, 2021, after a long struggle for about 10 years. It is basically a childhood cancer clinical study group in Asia to work with SIOP Asia as its action team, that is just like a Chinese proverb “Two Wheels of A Cart”. The structure of APHOG is still under construction, but we are now carefully and continuously making it.

We had the 1st APHOG Annual Meeting in 2022 through online, under the serious condition of COVID-19 pandemic. However, we could have the 2nd APHOG Annual Meeting 2023 in Yerevan, Armenia, together with the SIOP Asia Congress 2023 through hybrid system, that was made possible with a generous consideration of Dr. Gevorg Tamamyan, Armenia.

The 3rd APHOG Annual Meeting 2024 is now expanding the partnership with not only SIOP Asia 2024 but also St. Jude Global, and even the World Health Organization (WHO) as well as Pediatric Oncology East and Mediterranean (POEM) group. I would hope that as many people as possible having an interest in APHOG participate this exciting annual meeting and enjoy it.

Lastly, we would very much appreciate Prof. Guillermo Chantada, President of SIOP, and Prof. Hiroki Hori, Continental President of SIOP Asia, for their great support and collaboration,

Sincerely,


A handwritten signature in black ink, which appears to read "A. Nakagawara". The signature is written in a cursive, flowing style.

Akira Nakagawara, MD, PhD
Chair, Executive Council, APHOG

APHOG Annual Meeting 2024

June 24th MON,2024 (Yokohama Pacific,Japan)

Program



APHOG Annual Meeting 2024
June 24th MON, 2024 (Yokohama Pacific, Japan)

Joint Symposium of “SIOP Asia 2024”, “APHOG Annual Meeting 2024” and “St. Jude Global” (Room A)

8:00–10:00 Childhood and AYA Cancers Global Network Symposium–1

~ Partnering for CureALL ~

Chairs: Guillermo Chantada, Spain & Kimikazu Matsumoto, Japan

“WHO GICC: Action report” (tentative)

Andre Ilbawi, WHO

“SIOP” (tentative)

Guillermo Chantada, Spain

“SIOP and APHOG”

Muhammed Saghir Khan, Saudi Arabia

“St. Jude Global” (tentative)

Catherine Lam, USA

“APHOG to fight against pediatric and AYA cancers in Asia”

Akira Nakagawara, Japan

“POEM Group: advancing pediatric oncology in the East and Mediterranean Region”

Gevorg Tamamyran, Armenia

10:00–10:15 Coffee Break

10:15–11:55 Childhood and AYA Cancers Global Network Symposium–2

~ Current Problems and Future Action in Asia ~

Chairs: Catherine Lam, USA & Bharat Agarwal, India

“Epidemiology of Childhood Cancer in Asia”

Kayo Nakata, Japan

“Childhood Cancer Predisposition in Asia”

Catherine Lam, USA

“Facing with the challenge of changes in the diagnostic paradigm for pediatric cancers”

Godfrey Chan, China

“Radiotherapy in Asia”

Hiroshi Fuji, Japan

“Clinical Studies of Pediatric Cancers in Asia”

Chi-Kong Li, China

Luncheon Seminar (Room B)

12:00–13:00 “Advances in Immunotherapy of Pediatric Cancers”

Alice L. Yu, Taiwan

Chair: Bharat Agarwal, India (Sponsored by APHOG & NGO-MOCC)

<Break time>

APHOG Session-1 (Room B)

13:15-15:00 Status reports on WHO-GICC in focus countries in Asia
Chairs: Hiroki Hori, Japan & Muhammad Saghir Khan, Saudi Arabia

- “What is WHO GICC on-going?”
Yuliya Lyamzina, Czech Republic (WHO)
- “WHO GICC in Sri Lanka: Lessons Learned”
Sanjeeva Gunasekera, Sri Lanka
- “Status report on GICC in a focus country: Myanmar”
Aye Aye Khaing, Myanmar
- “WHO GICC – Philippines Milestones and Ten Strategic Goals”
Ana Patricia Alcasabas, Philippines
- “WHO GICC in Kyrgyzstan”
Sultan Stambekov, Kyrgyzstan
- “The perspective of Pediatric Familial Cancers in resource-limited Setting”
Alia Ahmad, Pakistan
- Invited Comments
Catherine Lam, USA & Elick Narayan, Republic of Fiji (WHO)

15:00-15:15 Coffee Break

APHOG Session-2 (Room B)

15:15-17:00 Challenges of Pediatric Cancer Clinical Trials in Asia
Chairs: Rashmi Dalvi, India & Purna Kurkure, India


- “SIOP Global Mapping Project in Asia”
Maite Gorostegui Obanos, Spain
- “Japan Children’s Cancer Group (JCCG) : Overview”
Atsushi Manabe, Japan
- “Lessons learned in the Conduct of Co-operative Group Multicentre Clinical Trials in India – The INPHOG Experience”
Ramandeep Arora, India
- “Experiences for clinical trials from Chinese Children Cancer Group”
Yongmin Tang, China
- “Clinical Trials in Thailand (ThaiPOG)”
Panya Seksarn, Thailand
- “Problems of Survivorship in Asia” (tentative)
Rashmi Dalvi, India
- Discussion

17:00-18:00 **“APHOG Annual General Meeting 2024” (Room B)**

APHOG Annual Meeting 2024

June 24th MON,2024 (Yokohama Pacific,Japan)

Profile & Abstract



Morning Session (Room A)

**Joint Symposium of “SIOG Asia 2024”, “APHOG Annual Meeting 2024”
and “St. Jude Global”**

Childhood and AYA Cancers Global Network Symposium-1

~ Partnering for CureALL ~

Chairs: Dr. Guillermo Chantada & Dr. Kimikazu Matsumoto

Andre Ilbawi, M.D.

**Cancer Control Officer
Management of Noncommunicable Diseases Unit
Department for Management of Noncommunicable Diseases,
Disability, Violence and Injury Prevention (NVI)
World Health Organization**



Guillermo Luis Chantada MD, PhD

Hospital Sant Joan de Déu Spain
President, SIOP



【Biography】

Dr. Guillermo Luis Chantada MD, PhD is a pediatric oncologist in charge of the outreach program of the Pediatric Cancer Center Barcelona (PCCB) at the Hospital Sant Joan de Déu (Barcelona, Spain) and the scientific director of the Fundación Pérez Sremini (Montevideo, Uruguay). He is the President of the International Society of Pediatric Oncology (SIOP) and former president of the Latin American Society of Pediatric Oncology (SLAOP) and former co-chair of the Grupo de América Latina de Oncología Pediátrica (GALOP) and coordinator of the European Retinoblastoma Group (EURbG). His areas of research are mainly devoted to retinoblastoma, where he was published extensively, new therapies in neuroblastoma and lymphomas.

Muhammad Saghir Khan, MD

Assistant Consultant, Pediatric Hematology/Oncology
King Faisal Specialist Hospital and Research Center Al Madinah



【Profile】

Dr. Muhammad Saghir Khan is a practicing pediatric oncologist from Pakistan, currently working at Department of Pediatrics, King Faisal Specialist Hospital and Research Center Al Madinah, Saudi Arabia. He has been an active member of SIOP since 2012. He is currently serving as a Co-Chair of SIOP Global Health Network and SIOP Board of Directors (since 2019), with a distinct focus on collaboration with pediatric oncology professionals caring for children and adolescents with cancer in low- and middle-income countries (LMIC). As a former chair of SIOP Education and Training Committee, Saghir was instrumental in the launching of SIOP Childhood Cancer Early Diagnosis and Appropriate Referral (CEDAR) project, in collaboration with the International Pediatric Association (IPA). He is also serving as a member of Executive Committee for Asian Pediatric Hematology and Oncology Group (APHOG) since its inception. He had served Pediatric Oncology East Mediterranean (POEM) Group as a former chair of POEM Training Working Group. He has contributed as leader/member of scientific committees for several National, Regional and International Pediatric Oncology Conferences. He played vital role as Scientific Co-Chair of SIOP Asia 2019 held at Abu Dhabi.

【Abstract】

SIOP Global Health Network and Collaborative Avenues for Healthcare Providers from Low Resource Settings

International Society of Pediatric Oncology, SIOP with a vision of “No child should die of cancer: cure for more, care for all” is the only global multidisciplinary society entirely devoted to pediatric and adolescent cancer. SIOP has over 3000 members worldwide including doctors, nurses, other healthcare professionals, scientists, and researchers. SIOP offers enormous opportunities to engage with fellow members and contribute to the development of the pediatric oncology field. At present, seven active networks are welcoming new members comprising Global Health Network, Nursing Network, Nutrition Network, Paediatric Psycho–Oncology (PPO) Network, Supportive Care Network, Women Leaders in Paediatric Oncology Network and Young SIOP Network.

The SIOP Global Health Network (GHN), formerly known as SIOP PODC, is focused on addressing the unmet needs of children with cancer by fostering practical guidance for delivering cancer care for health professionals caring for children living in low-resource settings. SIOP GHN has evolved into a global forum for multidisciplinary collaboration on research, education, and advocacy, in line with SIOP’s Vision and Mission. SIOP GHN is in a transformation process for a better alignment with SIOP’s strategic goals. SIOP GHN has seven active Working Groups including Palliative Care, Innovation and Research, Pediatric Radiation Oncology (PROS), Traditional and Complimentary Medicines, Partnership, Adolescents and Young Adults, and Psychosocial Well-being Working Groups. The presentation titled “SIOP Global Health Network and Collaborative Avenues for Healthcare Providers from Low Resource Settings” will highlight various opportunities that SIOP Global Health Network offers to Pediatric Oncology Communities in low-resource settings and potential collaboration with Asian Pediatric Hematology and Oncology Group (APHOG).

Catherine Lam, MD, MPH

Director of the Asia Pacific Regional Program and Health Systems Unit, St. Jude Global, and co-director of the World Health Organization Collaborating Centre for Childhood Cancer, U.S.A



【Profile】

Dr. Catherine Lam from St. Jude Children's Research Hospital is the founding Director of the WHO Collaborating Centre for Childhood Cancer, the Director of the Health Systems Unit, and the Director of the Asia Pacific Regional Program at St. Jude Global. In the clinic, she is a pediatric hematologist/oncologist who specializes in solid and rare tumors. Beyond the clinic, she is an Associate Professor, clinician scientist, and faculty director of the Global Child Health MSc program Health Systems and Policies course at the St. Jude Graduate School of Biomedical Sciences. Across these roles, she works with ministries and national programs to apply systems science and policy research to improve outcomes and deliver innovations at scale for children with cancer globally. Dr. Lam has championed the Global Initiative for Childhood Cancer (GICC) from its inception, including being instrumental in developing the initial blue sky concept proposal at St. Jude and the subsequent **CureALL** framework underpinning GICC, serving as Consultant in cancer control at the World Health Organization in Geneva from 2018 to 2019, and continuing to lead GICC implementation efforts at the WHO Collaborating Centre for Childhood Cancer with the St. Jude Global family. She has held a number of leadership roles globally, and works with various UN agencies and partners, including as Chair of the Country Selection working group for the Global Platform for Access to Childhood Cancer Medicines, co-Chair of the Implementation working group for strengthening childhood cancer registration with the International Agency for Research on Cancer, and as Founder and Lead for the global Childhood Cancer Essential Diagnostics working group and the National Cancer Control Planning integrating Children, Adolescents & Young Adults program engaging ministry-led teams across all six WHO regions.

Akira Nakagawara, MD, PhD

Chair, Executive Council, APHOG

Saga Heavy Ion Medical Accelerator in Tosu (HIMAT) Foundation, Japan



【Profile】

Dr. Akira Nakagawara graduated from Kyushu University School of Medicine in 1972. During his medical student days, he decided his life work as to elucidate the molecular and genetic mechanism of spontaneous regression of neuroblastoma. He worked as a pediatric surgeon for 14 years before moving to the genetic and genomic researcher of neuroblastoma. He was trained and learned at the Rockefeller University, NY, the Washington University, St. Louis, and the University of Pennsylvania, Philadelphia, USA. He was appointed to be the Director of Chiba Cancer Center Research Institute in 2004, President of Chiba Cancer Center in 2009, CEO of Saga Medical Center KOSEIKAN in 2014, and CEO of Saga HIMAT Foundation (heavy carbon particle beam therapy) in 2015. He was the continental president of SIOP Asia (2010–2015), President of the 50th SIOP 2018 in Kyoto, and is currently Chairman of the Executive

Council, APHOG. Recently, he was awarded the Austria Albert Schweitzer Prize 2023.

He published more than 410 peer-reviewed papers in N. Engl. J. Med., Nature, Lancet, Nature Med., Cancer Cell, J. Clin. Invest., Mol. Cell. Biol., J. Biol. Chem., etc.

【Abstract】

APHOG: Asian Pediatric Hematology and Oncology Group to fight against pediatric and AYA cancers in Asia

Asia is a huge and heterogeneous continent with about 60% of world population in more than 50 countries. The number of children with cancer has been reported as ~250,000 per year among which about 90% children live in low- and middle-income countries (LMICs) whose cure rate is less than 30%, leading to the WHO Global Initiative for Childhood Cancer (GICC).

Asian Pediatric Hematology and Oncology Group (APHOG) was officially founded in March 2021, but the first action demanding its establishment had happened in Yogyakarta, Indonesia, in 2012 among the Asian leaders participated in the SIOP Asia 2012 congress. APHOG aims to provide a practical platform for promotion of international clinical trials in Asian countries to raise the cure rate and better care for the children and AYA with cancer in Asia (Pediatr. Hematol. Oncol. J., 2020; JCO Glob. Oncol., 2023). The main projects includes the collaborative clinical studies to develop new drugs, promotion of the childhood cancer registry and diagnosis, solution of the genetic problems of childhood cancers, support for the better survivorship, construction of the ICT-based children's cancer global network system, and prevention of the late effects in Asia.

The structure of APHOG is still immature but steadily being constructed (APHOG Annual Report 2023). The key persons of many national clinical study groups for childhood cancer in Asia like CCCG, INPHOG, JCCG, TPOG, KPHOG, ThaiPOG and RSPOH are appointed to be the members of APHOG Executive Council or Advisory Board. Overcoming many difficulties, APHOG will go forward in global collaboration with SIOP/SIOP Asia, WHO, POEM, St. Jude Global, COG, etc.

Gevorg Tamamyan, MD, MSc, PhD, DSc

Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center:
Yerevan State Medical University, Armenia



【Profile】

Gevorg Tamamyan, MD, MSc, DSc is the Head of the Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center, Chairman and Professor of the Department of Hematology and Pediatric Oncology at Yerevan State Medical University, CEO of the Immune Oncology Research Institute, President–Elect of the Pediatric Oncology East and Mediterranean (POEM) Group, Chairman of the Board of the Institute of Cancer and Crisis, and the Editor–in–chief of OncoDaily. He is a Co–Founder and Board Member of the Armenian Association of Hematology and Oncology and the City of Smile Charitable Foundation. Dr. Tamamyan is the Past–Chair of the ASCO IDEA Steering Group and SIOP PODC Supportive care WG, Ambassador of the Society of Hematologic Oncology. He was selected for the ASCO Leadership Development Program and currently is a member of the ASCO International Committee. He is a recipient of numerous awards and distinctions, among them the ASCO IDEA and LIFe Awards, 40 under 40 in Cancer Award, he was recognized as a Young Leader of the International Agency for Cancer Research (IARC) and Union for International Cancer Control (UICC) .

【Abstract】

POEM Group: advancing pediatric oncology in the East and Mediterranean Region

The Pediatric Oncology East and Mediterranean (POEM) Group was established in 2013 as a cooperative platform for healthcare professionals in pediatric oncology from countries in the East and Mediterranean region. The goal is to share knowledge, start cooperative trials, and develop common approaches to provide the best possible care for children with cancer in the area. The group currently includes 110 centers and > 800 members from 28 countries. The mission is to continuously improve pediatric oncology care through capacity building, research, training, and advocacy. The vision is to ensure that every child with cancer in the region has equitable access to the highest quality care.

POEM Group is governed by the Board of Directors. It's led by the Executive Committee and the President elected by the Board. To facilitate scientific exchange and collaboration, the POEM Group organizes a biennial congress. The last one was in Oman in 2023 and the upcoming one is in Jordan in 2025. Many POEM Group members are also active members in other major pediatric oncology organizations, such as SIOP/SIOP Asia and APHOG. This overlap in membership naturally creates complementary efforts and synergies between these groups. Looking ahead, there is a recognized need for increased synchronization and collaboration, not only at the individual member level, but also at the organizational level, between the POEM Group and its peer associations. By aligning strategies and leveraging each other's strengths, these groups can further strengthen the collective impact on improving pediatric oncology care across the Asian region and globally.

**Childhood and AYA Cancers Global Network Symposium-2
- Current Problems and Future Action in Asia -**

Morning Session (Room A)

**Joint Symposium of “SIOP Asia 2024”, “APHOG Annual Meeting 2024” and
“St. Jude Global”**

Childhood and AYA Cancers Global Network Symposium-2


~ Current Problems and Future Action in Asia ~

Chairs: Dr. Catherine Lam & Dr. Bharat Agarwal

Childhood and AYA Cancers Global Network Symposium-2
- Current Problems and Future Action in Asia -

Kayo Nakata, MD, PhD

Cancer Control Center, Osaka International Cancer Institute, Japan



【Profile】

Kayo Nakata graduated from Nara Medical University in 2003. Following this she worked as a paediatrician and paediatric oncologist at the Nara Medical University Hospital and the Children's hospital in Osaka until 2012. Having developed a keen interest in the epidemiology of cancer in children, adolescents, and young adults, she joined the Osaka Cancer Registry where she is a Section Chief. In 2016-17, she worked as an Honorary Research Associate at the Developmental Biology and Cancer Programme, Institute of Child Health, University College London. She is the Chairperson of the Childhood, Adolescent, and Young Adult Cancer Control Subcommittee of the Osaka Prefectural Cancer Control Promotion Committee.

【Abstract】

Epidemiology of childhood cancer in Asia

According to GOBOCAN, 280 000 children and adolescents (aged 0-19 years) were newly diagnosed with cancer worldwide, and more than 105 000 children and adolescents died of cancer, with half of these cases in Asia, which has the largest population. In 2018, the World Health Organization launched the Global Initiative for Childhood Cancer, the goal of achieving at least 60% survival for childhood cancer globally by 2030. However, only about 13% of the world's population of children is covered by cancer registries, which provide the data required to monitor and track progress in the fight against cancer. St. Jude Children's Research Hospital and International Agency for Research on Cancer launched a bilateral collaborative agreement called "Targeting Childhood Cancer through the Global Initiative for Cancer Registry Development (ChildGICR)" in May 2020. The overall aim of this collaboration is to improve the quality and availability of data on cancer in children, particularly in countries with limited resources. The speaker is participating in this ChildGICR Masterclass as an Asian member. This presentation will share epidemiological information on the burden of childhood cancer and survival in Asia compiled by the members of the ChildGICR Masterclass.

Childhood and AYA Cancers Global Network Symposium-2
- Current Problems and Future Action in Asia -

Catherine Lam, MD, MPH

Director of the Asia Pacific Regional Program and Health Systems Unit, St. Jude Global, and co-director of the World Health Organization Collaborating Centre for Childhood Cancer, U.S.A



【Profile】

Dr. Catherine Lam from St. Jude Children's Research Hospital is the founding Director of the WHO Collaborating Centre for Childhood Cancer, the Director of the Health Systems Unit, and the Director of the Asia Pacific Regional Program at St. Jude Global. In the clinic, she is a pediatric hematologist/oncologist who specializes in solid and rare tumors. Beyond the clinic, she is an Associate Professor, clinician scientist, and faculty director of the Global Child Health MSc program Health Systems and Policies course at the St. Jude Graduate School of Biomedical Sciences. Across these roles, she works with ministries and national programs to apply systems science and policy research to improve outcomes and deliver innovations at scale for children with cancer globally. Dr. Lam has championed the Global Initiative for Childhood Cancer (GICC) from its inception, including being instrumental in developing the initial blue sky concept proposal at St. Jude and the subsequent **CureAll** framework underpinning GICC, serving as Consultant in cancer control at the World Health Organization in Geneva from 2018 to 2019, and continuing to lead GICC implementation efforts at the WHO Collaborating Centre for Childhood Cancer with the St. Jude Global family. She has held a number of leadership roles globally, and works with various UN agencies and partners, including as Chair of the Country Selection working group for the Global Platform for Access to Childhood Cancer Medicines, co-Chair of the Implementation working group for strengthening childhood cancer registration with the International Agency for Research on Cancer, and as Founder and Lead for the global Childhood Cancer Essential Diagnostics working group and the National Cancer Control Planning integrating Children, Adolescents & Young Adults program engaging ministry-led teams across all six WHO regions.

【Abstract】

Childhood and AYA Cancers Global Network Symposium-2 - Current Problems and Future Action in Asia -

Godfrey Chi-Fung Chan,

LMCHK, MD (UE, Phil), DMD (UE, Phil), MD (HKU), MSc (U Birmingham, UK),

MRCPCH (UK), FHKAM, FHKCPaed, FRCP (Edin), FRCPC (UK)

Specialist in Paediatric Haematology / Oncology, Director, Pediatric Hematology Oncology Centre,
Hong Kong Sanatorium & Hospital Cancer Centre, Honorary Clinical Prof., The University of Hong Kong,
Honorary Consultant, Hong Kong Children's Hospital, Honorary Consultant, HKU-Shenzhen Hospital, Hong Kong



【Profile】

Prof. Chan was trained under the Department of Pediatrics, HKU (1989-1992), then he pursued fellowship training in Pediatric Hematology Oncology at the St. Jude Children's Research Hospital, USA (1993-1996). He subsequently obtained Dip of Palliative Medicine (U Wales, 1997) and MSc (U Birmingham, 1999). He joined the HKU in 1999 and was promoted to Clinical Professor of HKU in 2009 and then was awarded Tsao Yen-Chow Endowed Professorship of Pediatrics in 2013. He served as the Head of the same Department from 2012 to 2022. He was the former Chief of Service of Departments of Pediatrics & Adolescent Medicine, Queen Mary Hospital (2012-2018); Hong Kong Children's Hospital (2018-2022); and HKU-Shenzhen Hospital (2012-2023). He published >400 indexed papers and is the current Chief Editor of HK Journal of Paediatrics. He joined the Paediatric Haematology Oncology Centre of HKSH Cancer Centre in July 2023. He is currently the Secretary of APHOG. His major research interests include immunotherapy for pediatric neurogenic tumors and the drug resistant mechanisms of cancer microenvironments.

【Abstract】

Facing with the challenge of changes in the diagnostic paradigm for pediatric cancers

Over the past 2 decades, with the rapid advances in technology, we witness rapid changes in various diagnostic approaches. For diagnostic imaging, one can combine the structural imaging (e.g., CT scan, MRI, etc.) with the functional imaging (e.g., PET scan) so we can assess the nature and location of the targeted lesion collectively. Functional imaging can also turn into therapeutic uses (also known as theranostics) by adopting different radioisotopes. Such as in neuroblastoma, I-123 can be changed to I-131 for MIBG and Ga-68 changes to Lu-177 for DOTATATE. They both have been applied clinically as therapeutic option. For pathological diagnosis, we have been relying on morphology and immuno-histochemistry as our gold standard in the past. However, molecular genetic diagnosis is becoming an essential tool and often the final verdict. Partly because molecular diagnosis can guide us more precisely for treatment such as targeted therapy. It can also more accurately reflect the prognosis. There are some confusions for the term "next generation sequencing (NGS)", it includes panel NGS, whole exome sequencing (WES), and whole genome sequencing (WGS). They all have their own advantages and limitations. Recently, epigenetic methods such as methylation profiling has been used successfully to stratify subtypes of pediatric brain tumors and sarcomas. Molecular and epigenetic markers (e.g. micro-RNA) can also serve as disease monitoring tool as well. Familiar with all these advancements will help us to manage our patients more accurately and effectively. On the other hand, whether all these advancements can be practically applied to all Asian countries remain a big question. Efforts should be made to facilitate knowledge transfer, networking and financial support for healthcare workers involved in caring for children with cancers.

Hiroshi Fuji, MD, PhD

Head, Division of Radiation Oncology
National Center for Child Health and Development, Japan



【Profile】

Dr. Hiroshi Fuji is a radiation oncologist at the National Center for Child Health and Development (NCCHD), Tokyo, Japan. Dr. Hiroshi Fuji is dedicated to chairing the radiation oncology committee in the Japan Children's Cancer Group (JCCG). With a deep passion for pediatric oncology, Dr. Hiroshi Fuji provides compassionate care and innovative treatment solutions to young patients battling cancer. Prior to joining NCCHD, Dr. Hiroshi Fuji was responsible for introducing proton beam therapy and establishing its indication as one of the pioneers of pediatric proton beam therapy in Japan at Shizuoka Cancer Center. In addition, Dr. Hiroshi Fuji played a crucial role in managing and overseeing nationwide clinical trial to build a clinical evidence of proton beam therapy. Through his expertise in radiation therapy and commitment to leading clinical trials, Dr. Hiroshi Fuji strives to make a positive

impact in the lives of children and families facing these challenges.

【Abstract】

Radiotherapy in Asia (tentative)

Economic status and social support often affect the installation of radiotherapy equipment and the availability of qualified radiotherapy staff. Due to the rarity of pediatric cancers, these infrastructure issues need to be addressed through national activities or international collaborations. Clinical trials conducted by European or North American groups have helped to establish standard treatment for solid tumors. Asian countries have had limited opportunities to participate in these trials. As a result, oncologists in Asia learn about the new treatment and its importance only after these trials are published. This outdated and limited information from the published report prevents the replication of the protocol treatment and the perception of the actual applicability of even a standardized treatment. These issues were critical in radiation oncology, which was rarely described in detail in the published work. Proton beam therapy, known to be the preferred radiotherapy for pediatric cancer, is increasingly available in Asia. The increasing number of proton therapy systems may improve the quality of radiotherapy for childhood cancer in Asia. However, the effective delivery of proton beam therapy for childhood cancer will be achieved through the concentration of applicable patents and the implementation of support services to designated proton beam therapy institutes. Mutual communication and cooperation among Asian countries is essential to solve our unique problems.

Childhood and AYA Cancers Global Network Symposium-2
- Current Problems and Future Action in Asia -

Chi-kong LI, MBBS, MD

Department of Paediatrics, The Chinese University of Hong Kong, The Hong Kong Children's Hospital,
Hong Kong (China)



【Profile】

Prof. Chi-kong LI currently is Research Professor at Department of Paediatrics of The Chinese University of Hong Kong, and honorary consultant at Hong Kong Children's Hospital. He had been Chief of Service of Department of Paediatrics, Prince of Wales Hospital at Hong Kong from 2004 to 2014. He was the past Continental President of Asia of International Society of Pediatric Oncology. He is the Director of Committee of Subspecialty Boards of Hong Kong College of Paediatricians. His research interest is acute lymphoblastic leukaemia (ALL), cellular therapy and thalassaemia. He has been the coordinator of ALL studies in Hong Kong since 1993, and also serves as co-principal investigators of several national ALL studies in China. Internationally he is a member of IBFM Study Group, and have participated in several international clinical trials for subtypes of ALL. He was the founding chairman

of Hong Kong Society of Children's Palliative Care in 2017.

【Abstract】

Clinical studies of pediatric cancers in Asia

Cancer in children is rare with annual incidence of about 130 new cases per million children. There was great advance in the management of childhood cancers in past few decades and about 70-80% of children with cancer are now long-term survivors in High Income countries (HIC). The improvement of survival outcome is contributed by multiple factors, large multi-center clinical trials (MCCT) play very important role. HIC in Asia also conducted successful MCCT in some pediatric cancers, Japan has a longer history in organizing the clinical trials. Some Middle-income countries (MIC) just started MCCT in the recent 10-20 years but most are not on a national basis, such as China and Malaysia. Low-income countries (LIC) are struggling for resources to achieve standard of care treatment, MCCT is the next step after elevating the treatment standard such as India. Some of the HIC in Asia do not engage much in MCCT but rather than developing more advanced therapy for cancers at individual center base. The challenges of conducting MCCTs are very different among countries in Asia, including infrastructure of trial centers, funding support for the operation, availability of diagnostic studies and medications, patients and families consent for research studies.. etc. With collaboration of centers and support from international organizations, more MCCT may be developed according to the local situation in Asia. Asian Pediatric Hematology & Oncology Group (APHOG) aims to enhance and facilitate MCCT in Asia and hope that more colleagues can provide inputs and suggestions to realize the objectives.

**Luncheon Seminar
“Advances in Immunotherapy of Pediatric Cancers”**

Luncheon Seminar (Room A)

Date & Time: June 24th MON 12:00–13:00 JST

Venue: Room A, Yokohama Pacific

Chair: Dr. Bharat Agarwal, India

Advances in Immunotherapy of Pediatric Cancers

Alice L. Yu, Taiwan

**Sponsored by Asian Pediatric Hematology and Oncology Group (APHOG) and
NGO Magokoro Organization for Childhood Cancer (MOCC)**



Luncheon Seminar
“Advances in Immunotherapy of Pediatric Cancers”

Alice L. Yu, MD, PhD

**Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial
Hospital, Taiwan**



【Profile】

As a pioneer in cancer immunotherapy, Dr. Yu has taken an anti-GD2 monoclonal antibody (Dinutuximab) from preclinical to phase III clinical trial, culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent to target glycolipids worldwide. She has continued to improve the efficacy of anti-GD2 immunotherapy through international collaboration. Her group has demonstrated the adverse impact of Globo H /SSEA3 expression on the outcome of patients with hepatoma, cholangiocarcinoma, and gallbladder cancer. She also uncovered the roles of Globo H in cancer as an immune checkpoint molecule and angiogenic factor, providing rationales for the ongoing development of Globo H-targeted immunotherapeutics. She has received many awards, including the Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020, Excellence in Technology Transfer Award from Federal Laboratory Consortium (USA) in 2016, The 55th Academic Award from the Ministry of Education (Taiwan), Year 2000 “Key to Life” Award, Leukemia & Lymphoma Society (USA), etc.

【Abstract】

Advances in Immunotherapy of Pediatric Cancers

Although immunotherapy has emerged as a mainstay in adult cancer treatment, its use in pediatric cancers remains limited, except for anti-GD2 for neuroblastoma and CD19 targeted bispecific antibody or CAR T cell therapy for ALL. Long term follow up of CAR T therapy revealed development of CAR⁺ T cell malignancies, prompting FDA to issue a safety communication on 11/28/2023, but the benefits continue to far outweigh their risks in the setting of relapsed/refractory malignancies. In the arena of immune checkpoint inhibitors for pediatric use, FDA approval has been limited to melanoma and MSI-H or dMMR solid tumors in children >12y, Hodgkin’s lymphoma, mediastinal large B-cell lymphoma and metastatic Merkel cell carcinoma.

APHOG Session-1 (Room B)

Status reports on WHO-GICC in focus countries in Asia

Chairs: Dr. Hiroki Hori & Dr. Muhammad Saghir Khan

APHOG Session-1
Status reports on WHO-GICC in focus countries in Asia

Yuliya Lyamzina, PhD, MBA

Dr Sanjeeva Gunasekera, MBBS, MD, MSc

National Cancer Institute Sri Lanka, Sri Lanka



【Profile】

Dr. Gunasekera is a paediatric oncologist working in the National Cancer Institute Sri Lanka and he is also holds adjunct teaching appointments in Universities of Peradeniya and Sri Jayawardenapura. Dr. Gunasekera is the immediate past Secretary of the Sri Lanka College of Oncologists. He is a member of the National Advisory Committee for Cancer Control and a focal point for WHO Global Initiative for Childhood Cancer in Sri Lanka.

Dr. Gunasekera is the Convenor of the Sri Lanka Cancer Research Group and an Academic Editor of the PLOS Global Health journal as well as the founding Editor of the Sri Lanka Journal of Cancer. He has research interest in Sarcomas, Improving access to medicine, cancer policy etc and has published over 50 journal articles in peer reviewed journals. He also been a past winner of the SIOP Young Investigator award as well as the SIOP Global Health Scholarship.

【Abstract】

WHO Global Initiative for Childhood Cancer (GICC) in Sri Lanka: Lessons Learned

Sri Lanka has a population of nearly 22 million people and has a free public sector health care system. More than 800 new children with cancer is diagnosed each year and vast majority of them are treated at the National Cancer Institute Sri Lanka (NCISL). Sri Lanka was selected as focus country for the WHO GICC in 2021 as the second country from the WHO South East Asia Region.

A steering committee representing physicians, policy makers, civil society, development partners identified capacity building of the workforce, quality improvement and expansion of the childhood cancer services, establishing a childhood cancer registry as well as strengthening the policy landscape as the priority areas for early focus. Currently seven activities covering the above areas have been completed with two more under in progress.

Strong political will, multi stakeholder decision making resulting in strong buy-in at the implementing stage, ability to leverage on existing partnerships and opportunity to create goal focused teams were the main factors that played a major role in the successful implementation of the activities of GICC in Sri Lanka. However, significant challenges were encountered in this process and some of them were – Vulnerability for disruption by un anticipated external forces such as the Covid 19 pandemic and the subsequent economic crisis in Sri Lanka, Lack of manpower precluding wider expansion of activities and persisting uncertainty of how best to sustain the gains achieved post the immediate intervention period.

Aye Aye Khaing, MD

Yangon Children's Hospital, Myanmar, Myanmar



【Profile】

Pediatrician after local MMed Sc Paed education in 1997. obtained MRCPCH UK in 2001. Served as a pediatric hemato oncologist in 2003 at the biggest tertiary referral center, Yangon Children's Hospital, received clinical fellowship training in Paediatric Hemato Oncology in 2013-2014 from KK Women's and Children's Hospital Singapore. Obtained Dr Med Sc Paed in 2017 and becomes an honorary fellowship of RCPCH since 2021.

Currently serving as a Professor and Head of the department of Pediatric Hemato - Oncology, University Medicine I, Yangon, running a pediatric hemato oncology doctorate program. Also a program manager of WHO CCI program in childhood cancer control in Myanmar since 2019 as a first focus country in ASIA. Also a vice president of Myanmar Society of Hematology and member of Myanmar Pediatric Society.

【Abstract】

Status report on GICC in a focus country : Myanmar

WHO Global Initiative for Childhood Cancer (GICC) was launched by WHO in 2018 along with St. Jude Children's Research Hospital and other partners with the aim of achieving at least 60% global survival and reducing suffering for all children with cancer by 2030. Myanmar is the first focus country in SEA. In Myanmar, there was an estimate that there are 1500-2000 new childhood cancer patients aged 0-19 every year. Currently, a total of 700-800 new childhood cancer patients are identified annually in Myanmar, with more than 400 patients referred to Yangon Children's Hospital.

There are two pediatric hematology-oncology units, one is attached to Yangon Children's Hospital (YCH) to provide services for those patients come from lower part of Myanmar and another one is in 300-bedded Mandalay Children's Hospital (300-MCH) to provide services for those patients come from middle part of Myanmar. Through GICC biannual work plan starting from 2019, WHO supported in recruitment of staffs and supply of essential medicines for continuity of childhood cancer services which was severely affected by pandemic and country situation. Following the GICC support, collaboration with network hospitals became more active, patient review meeting revitalized, satellite center resource guides development continued, training to healthcare providers were continued virtually, and supply of essential medicine were sustained during the last 3 years by implementing the work plan which is in aligned with National Childhood Cancer Control Plan.

Ana Patricia Alcasabas, MD, MS-GCH

The Division Head of Pediatric Hematology-Oncology at the University of the Philippines-Philippine General Hospital (UP-PGH), Philippines



【Profile】

Dr. Alcasabas is the Division Head of Pediatric Hematology-Oncology at the University of the Philippines-Philippine General Hospital (UP-PGH). She earned her medical degree from the University of the Philippines and completed her Pediatrics and Hematology-Oncology fellowship at Wayne State University and the Children's Hospital of Michigan. Recently, she graduated with a Masters in Global Pediatric Medicine from the St. Jude Children's Research Hospital Graduate School of Biomedical Sciences. Before joining UP-PGH, Dr. Alcasabas served as a primary healthcare physician for the Mangyan tribe in Mindoro Island, Philippines, and as a pediatric oncology consultant at the National University Hospital, Singapore. Currently, Dr. Alcasabas chairs the Asian Childhood Cancer Alliance and the National Technical Working Group of Childhood Cancer. She led several WHO Global Initiative for Childhood Cancer projects, including a rapid baseline assessment of pediatric cancer care and

the development of a pediatric cancer patient navigation curriculum in the country.

【Abstract】

WHO GICC -Philippines Milestones and Ten Strategic Goals

The Philippines is the 1st WHO Global Initiative for Childhood Cancer Focus country in the Western Pacific Region. The launching event, held in Manila last September 25, 2019, was sponsored by St. Jude Children's Research Hospital, The Department of Health, WHO, and the Philippine Society of Pediatric Oncology (PSPO) and attended by 85 representatives from 62 government and private institutions. Together, the stakeholders created a draft national progress monitor to guide the implementation of the ten strategic goals for the Philippines, aligned with the WHO CUREA// elements and the country's National Integrated Cancer Control Act (RA 11215). From 2021-2023, there were seven funded and two supported projects. These included a rapid baseline assessment of the state of childhood cancer in the country and the development of a national cancer control plan, the creation of a patient navigation curriculum for pediatric cancer, and the expansion of the population-based pediatric cancer registry to survival data. Technical support from the WHO GICC facilitated the creation of the 1st National Technical Working Group for Childhood Cancer. Additionally, the Philippine government increased its investments in cancer infrastructure and medicines. Hence, there are ongoing projects for each of the ten core commitments. The continued national and international commitment and collaborations aim to elevate childhood cancer survival rates in the Philippines to 60% by 2030.

Stambekov Sultan. MD

Head of Pediatric oncology and Oncohematology Department of National Center of Childhood and Maternity, Bishkek, Kyrgyz Republic



【Profile】

Stambekov Sultan. MD. Head of Pediatric oncology and Oncohematology Department of National Center of Childhood and Maternity, Bishkek, Kyrgyz Republic. Lead oncopediatrician of Ministry of Health of Kyrgyz Republic. Regional Coordinator of Eurasian Association of Pediatric Oncologists (EURADO) Member of Global Alliance St. Jude. President of National Society of Pediatric oncologist and Oncohematologists of Kyrgyz Republic.

【Abstract】

WHO GICC in Kyrgyzstan (tentative)

The Global Initiative on Childhood Cancer (GICC) has emerged as a pivotal framework for enhancing childhood cancer control efforts worldwide. This article explores the transformative impact of Kyrgyzstan's participation in GICC since its inception. Through comprehensive analysis of key indicators and initiatives, this study aims to elucidate multifaceted changes observed in Kyrgyzstan's approach to childhood cancer control.

Firstly, the article examines improvements in access to quality cancer treatment for children. This includes enhancements in healthcare infrastructure, availability of medications, and development of specialized services.

Psychosocial support, palliative care have been integrated into the healthcare system, significantly improving the quality of life.

Kyrgyzstan started to collect data in monitoring childhood cancer, outcomes, survivorship. Through data management and analysis, Kyrgyzstan now is able to evaluate the effectiveness of interventions and guide strategies effectively.

Furthermore, the collaborative approach fostered by the GICC is examined, emphasizing partnerships among healthcare professionals, government agencies, NGOs, and stakeholders. Collaborative effort has facilitated knowledge-sharing, resource mobilization, and capacity-building initiatives, driving sustainable progress in childhood cancer.

The increased public awareness and community engagement resulting from Kyrgyzstan's participation in the GICC. Efforts to raise awareness about childhood cancer prevention, improved detection rates, and garnered widespread support for cancer control initiatives.

Kyrgyzstan's participation in the GICC has led to significant advancements in childhood cancer control, resulting in improved outcomes and better quality of life for affected children. This analysis underscores the transformative potential of international collaborations in addressing complex health challenges on a global scale.

APHOG Session-1
Status reports on WHO-GICC in focus countries in Asia

Alia Ahmad, MBBS, DCH, MRCPCH (UK), FRCPC (UK), MS-Global Child Health (USA)

Professor Paediatric Haematology / Oncology

University of Child Health Sciences & Children's Hospital Lahore Pakistan, Primary Delegate for St. Jude Global Alliance Partnership, Member Advisory Board St. Jude Together, Chairperson Punjab Cancer Registry Pakistan, Pakistan



【Profile】

Dr. Alia Ahmad MBBS DCH MRCPCH (UK), FRCPC (UK) MS-Global Child Health (USA) working as a Professor of Paediatric Haematology/Oncology at the University of Child Health Sciences, Children's Hospital Lahore Pakistan since 2011. She is also a Primary Delegate for the St. Jude Global Alliance Partnership since 2019 and was General Secretary Pakistan Society of Paediatric Oncology PSPO from 2018 to 2024. She is a Chairperson of the Punjab Cancer Registry and External Member Advisory Board of St. Jude Together and a member Steering Committee of ProFILE projects of St. Jude Children's Research Hospital have a great passion for the improvement of childhood cancer care in Pakistan through training the health workforce, capacity-building, and promoting community and health professional awareness and health literacy regarding childhood cancer. She has been the Team Lead for the NCCP-iCAYA series of workshops cohort-1 and cohort-2 (2023& 2024) organized by St. Jude Children's Research Hospital and the National Cancer Institute. She actively participated in the National Stakeholder Workshop organized by WHO Pakistan, PSPO, St. Jude Global, and WHO EMRO in September 2023. She is passionate about improving childhood cancer survival in the country by taking part in activities to improve capacity-building, training, and research using the GICC-CURE A// Framework. She is the Site Director for SJCARES Hospital-based Pediatric Cancer registry at Children's Hospital Lahore and Team Leads for Quality Improvement Projects of St. Jude Global Academy like Improvement Science in Action (ISIA) Global Comfort Process and Post-ProFILE Golden Hour.

【Abstract】 The Perspective of Pediatric Familial Cancers in resource-limited Settings

Background: Familial Cancers are not uncommon among the pediatric population. Therefore, the identification of such syndromes and families is important for active screening and early detection of cancer including brain tumors among those at risk of developing cancer through National cancer genetics study programs.

Methods: A retrospective cohort study was done in UCHS, Children's Hospital Lahore Pakistan to explore the Familial cancer syndromes being treated in the Oncology Department from January 2015 to June 2023.

Results: Among **RB families** of 30 cases, children presented early, and despite family history, multiple children expired before, during, or after treatment, and many of them refused curative treatment. Among **10 CMMRD/ Lynch syndrome families**, these children had brain tumors, colorectal carcinomas, and lymphoblastic Lymphomas with poor prognosis, and most of them expired during treatment. For children presenting with **familial HLH** and others having Chediak-Higashi Syndrome of 20 families with more than 30 children, many of the siblings expired due to the non-availability of stem cell transplantation. **Siblings** group had 20 families where siblings had brain tumors, Wilms tumor, Rhabdomyosarcoma, Neuroblastoma, Acute Lymphoblastic Leukaemia/Lymphoma, Hodgkin Lymphoma, and Burkitt Lymphoma with variable prognosis. **Parent and Child group** of 10 families having leukemia, lymphoma, Neuroblastoma, and CRC and only one parent was alive and the rest expired due to brain tumor, CA Breast, Lymphoma, AML, and gall bladder cancer. **Two siblings of the Li-Fraumeni family** expired from choroid plexus tumor grade II and CRC with two young aunts from CA Breast and CA Colon while one sibling is on treatment for.

Conclusion: These families require extensive psychosocial support with better surveillance means for early diagnosis and better management of all the index cases and at-risk family members in LMIC

Invited Comments:

Elick Ashwin Narayan MBBS. MMed (Oncology) , MFCGP, MFMA

【Profile】



Dr. Narayan is an Internal Medicine Specialist with sub-speciality in Medical Oncology who completed his Bachelor of Medicine and Bachelor of Surgery (MBBS) and Master of Medicine degree at Zhengzhou University in the Peoples People's Republic of China. Dr. Narayan has worked in remote areas of Fiji Islands at the Primary Health Centers as well as in tertiary care centers. He was the Dean of Umanand Prasad School of Medicine at the University of Fiji and was pivotal in implementing new programmes at the school. He has served as a full member of the Fiji Medical and Dental Council from 2017 to 2019, which is the registration, licensing and regulatory body for all health practitioners in Fiji. He is a full member of the Fiji Medical Association and the Fiji College of General Practitioners. Significant experience working with government ministries, international and regional development agencies, civil societies, and academic institutions in providing quality health services for people in the Asia-Pacific region.

Dr. Narayan was the Consultant Physician for the Republic of Nauru Hospital before joining WHO Western Pacific Regional Office. Dr Narayan joined WHO-WPRO as Technical Officer for NCD – Cancer control and has been leading the cancer control activities in the region since 2020.

APHOG Session-2 (Room B)

Challenges of Pediatric Cancer Clinical Trials in Asia

Chairs: Dr. Rashmi Dalvi & Dr. Purna Kurkure

APHOG Session-2
Challenges of Pediatric Cancer Clinical Trials in Asia

Maite Gorostegul Obanos, MD



【Profile】

I am a Pediatric Oncologist with more than fifteen years of experience treating children and adolescents affected by different cancers. Passionate about giving the best care to children and adolescents, my areas of research focus on neuroblastoma, germ cell tumors, nephroblastoma, and rare tumors. I am working at the Pediatric Cancer Center Barcelona, and I am also Chair of the SIOP Global Mapping Programme. I am collaborating as co-lead for the Group of Hereditary and Rare Tumors (Cure4kids platform) in Latin America.

I am committed to improving cancer inequalities and medical education. Following these goals, I joined the medical direction of the pediatric oncology platform TELEO and developed evidence-based medicine activities for my institution's hematology/oncology fellowship program.

Additionally, I started working on an international project to improve cancer care at St. John of God Hospital, Lunsar (SL), I am coordinating an educational program for oncology awareness in low-income countries, and I serve as Ambassador for Zero Abandonment.

I am a member of the Clinical Research Ethics Committee of the Fundació de Recerca Sant Joan de Déu and of the Editorial Board of Oncodaily.

【Abstract】

APHOG Session-2
Challenges of Pediatric Cancer Clinical Trials in Asia

Atsushi Manabe, MD, PhD

SIOP, ASH, Pediatric Blood Cancer, Japan



【Profile】

Professor Atsushi Manabe was born in Japan and graduated from Hokkaido University with MD in 1985. After training in pediatrics at St. Luke's International Hospital (SLH) in Tokyo, Dr. Manabe went to Catholic University of Rome as a visiting fellow and St. Jude Children's Research Hospital in Memphis as a post-doctoral fellow to study leukemia biology with Dario Campana. After returning to Japan, Dr. Manabe has been involved in clinical trials leukemia and myelodysplastic syndrome at SLH, Institute of Medical Science at University of Tokyo, and finally, he was appointed Chairperson of Pediatrics at Hokkaido University in 2019. Currently, Dr. Manabe is leading JCCG, which is a nationwide study group for childhood leukemia and solid tumors in Japan. Dr. Manabe is also active abroad and is a member of important academic societies such as SIOP and ASH. He has been an editor of Pediatric Blood Cancer.

【Abstract】

Japan Children's Cancer Group (JCCG) : Overview

The Japan Children's Cancer Group (JCCG) was established in 2014, merging the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG) and solid tumor study groups, including those focusing on brain tumor, neuroblastoma, Wilms' tumor, hepatoblastoma, rhabdomyosarcoma, Ewing sarcoma, and others. Unification of these study groups has enabled not only the registration of a large number of patients, but also the facilitation of translational research into the tumor cell biology and pharmacogenomics.

JCCG offers a variety of essential facilities which support clinical trials for children with cancer. These include a central laboratory for the diagnosis of cancer in children, including pathology, immunology, molecular biology, and diagnostic imaging. Centralized data centers and the storage of precious patients' samples are also important. We need experts in data management, biostatistics, and ethics, in addition to all healthcare professionals with various areas of expertise. Over the past 10 years, as many as 20,000 patients were registered in clinical trials for hematological malignancies whereas over 10,000 patients were registered in those for solid tumors. Importantly, most clinical trials were supported by the governmental funding such as AMED (Japan Agency for Medical Research and Development). Grants are awarded on a competitive basis. A large number of good results have come out and most of them were already published in biomedical journals.

I will talk about the structure of JCCG, some achievements of JCCG, and problems of JCCG at this precious occasion.

APHOG Session-2
Challenges of Pediatric Cancer Clinical Trials in Asia

Ramandeep Singh Arora DCH, MRCPCH, MD

Max Super Speciality Hospital, New Delhi, India



【Profile】

Dr Ramandeep Singh Arora, DCH, MRCPCH, MD is a pediatric oncologist at Max Healthcare, New Delhi, India. His interests include epidemiology, access to care and health systems. He is one of the directors of the Indian Pediatric Hematology Oncology Group which promotes collaborative research in India. Recently he has been involved with the Indian Childhood Cancer Initiative which aims to work with all stakeholders including the government as well as WHO to develop a national policy on childhood cancer.

【Abstract】

Lessons LEARNT IN THE Conduct of Co-operative Group Multicentre Clinical Trials in India-The INPHOG Experience

Treatment of children with cancer on clinical trials, often in the context of national and international co-operative groups, is one of the cornerstones of pediatric oncology treatment and has been shown to improve outcomes of children with cancer. While enrolling children with cancer in prospective multi-centre trials has become the norm in high-income countries, it has just started emerging in low and middle-income countries. Active since 2015, INPHOG has enrolled 15,000+ children with cancer in 30+ multicenter studies in 150+ participating institutions in India in the absence of formal funding for most studies. Presently, it is estimated that <5% of children with cancer treated in India got enrolled into collaborative clinical studies. The goal is to quadruple these participation rates by further optimising the operational framework, building capacity with dedicated research staff, seeking grants and other tapping other sources of funds, and collaborating with national and international partners.

APHOG Session-2
Challenges of Pediatric Cancer Clinical Trials in Asia

Yongmin Tang, MD

Affiliation: Division/Center of Pediatric Hematology-Oncology at the Children's Hospital of Zhejiang University School of Medicine; National Medical Research Center for Child Health, China



【Profile】

Professor/Dr. Tang obtained his MD degree in 1982 and trained in Japan and USA. He is currently the academic leader of the Division/Center of Pediatric Hematology/Oncology at Children's Hospital of Zhejiang University School of Medicine. He was the immediate former Chairman of Chinese Children's Cancer Group (CCCG), China Anti-Cancer Association and the Scientific Committee Board Member of Histiocyte Society. He is currently the Advisory Board Member of Asia Pediatric Hematology-Oncology Group (APHOG), Members of SIOP and ASH. His main interests are the diagnosis and treatment of childhood hematology-oncology diseases, including immunological diagnosis and chemoimmunotherapy and related laboratory researches on flow cytometric detection of MRD on childhood hematological malignancies, antibody engineering and drug development. He is also active in managing the pediatric patients with hemophagocytic lymphohistiocytosis (HLH) in the area of early diagnosis and stratified treatment based on cytokine detection and monitoring.

【Abstract】

Experiences for clinical trials from Chinese Children Cancer Group

Clinical trials have demonstrated very important evidence for clinical practice. However, clinical trials especially multi-centered randomized and prospective clinical trials present even more challenges including lots of man-power, well organized, commitment and dedication as well as research funds. In this talk, I would like to give a brief introduction of childhood cancer diagnosis/treatment study groups in China particular about Chinese Children's Cancer Group (CCCG) and its development. I would also like to present brief introduction of several representative successful clinical trials and outcomes in China such as CCCG-ALL-2015, CCLG-APL-2016 protocols conducted during the recent years to provide models for more clinical trials in the future. Recent advances in the next-generation sequencing (NGS) to precisely detect minimal residual diseases (MRD) to compare to other approaches such as multi-parameter flow cytometer, digital PCR etc. to guide the protocol options and outcome predictions during clinical trial in our own group. I would also like to briefly introduce some translational researches on new therapeutic approaches and new drug development focusing on childhood cancer. Finally, I would like to present the current challenges we are facing now and the possible solutions to launch successful clinical trials in the future for Chinese children with either hematological malignancies and/or solid tumors.

APHOG Session-2
Challenges of Pediatric Cancer Clinical Trials in Asia

Panya Seksarn M.D.

Visiting Prof. at Department of Pediatrics, King Chulalongkorn Memorial Hospital, Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand.



【Profile】

Currently serve as Visiting Professor at the Division of Hematology/Oncology, Department of Pediatrics, King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. As the former chairman of the Thai Pediatric Oncology Group and vice president of the Thai Society of Hematology, he has played pivotal roles in shaping the landscape of pediatric cancer care in Thailand. His leadership was evident in organizing SIOP Asia 2017 in Bangkok, a significant international conference that brought together experts and professionals in pediatric oncology from across the region. Additionally, his contributions extend to regional platforms such as the APHOG advisory board and SIOP Asia, where he continues to advocate for advancements in pediatric oncology. Within Thailand, he remains actively involved in various Pediatric Hematology/Oncology committees, serving as the Chairman of the Pediatric Hematology/Oncology Subboard training program, membership in the National Drug List and advisory board to the National Health Security Office underscores his commitment to ensuring access to essential treatments for childhood leukemia/lymphoma and stem cell transplantation. Furthermore, his scholarly contributions are evident through the publication of nearly 35 papers in international journals over the past 20 years, reflecting his dedication to advancing knowledge and practice in Pediatric Hematology/Oncology. Overall, his multifaceted roles and accomplishments underscore his significant impact on pediatric cancer care and research in Thailand.

【Abstract】

“Clinical Trials in Thailand (ThaiPOG)” (tentative)

Thai Pediatric Oncology Group (ThaiPOG) plays a pivotal role in advancing pediatric cancer care in Thailand. Established in 2002, it serves as a unified body for pediatric hematologist/ oncologists across the nation, working under the Thai Society of Hematology (TSH). With over 150 members and 40 registered pediatric cancer treatment centers. ThaiPOG focuses on optimizing treatment guidelines and protocols tailored to childhood cancers in Thailand. Collaboration with the National Health Security Office has been instrumental in establishing and regularly updating standard treatment protocols for childhood cancers, ensuring full reimbursement by the government. Moreover, ThaiPOG actively engages in multicenter research endeavors, supported by funding from TSH and other resources. These studies cover a wide range of topics, including childhood cancer incidence and survival rates, outcomes of specific cancers like acute lymphoblastic leukemia, central nervous system tumors, and high-risk neuroblastoma. Additionally, research efforts delve into clinical manifestations of specific conditions like Langerhans cell histiocytosis and germline mutations in hemophagocytic lymphohistiocytosis (HLH). The impact of ThaiPOG's research extends beyond academia, influencing health policy in Thailand. For instance, evidence from studies led to the inclusion of topotecan in the national drug list for treating high-risk neuroblastoma patients. ThaiPOG continues its efforts with ongoing projects such as establishing a high-quality pediatric cancer registration system in Thailand. This initiative aims to support cancer-specific strategic planning and collaborative research efforts. Additionally, ongoing research into the prevalence of HAVCR2 mutations among Thai pediatric HLH patients underscores ThaiPOG's commitment to advancing understanding and treatment of childhood cancers in the region.

APHOG Session-2
Challenges of Pediatric Cancer Clinical Trials in Asia

RASHMI DALVI MBBS, MD, DCH

Professor & Head, Dept of Pediatrics , Consultant Pediatric Hematologist Oncologist
Bombay Hospital Institute of Medical Sciences
Visiting Consultant, NH-SRCC Children's Hospital
Visiting Faculty PHO & BMT: LTMG Medical College & Hospital Mumbai, India



【Profile】

Immediate Past Continental President SIOP Asia (2018-2021)
APHOG : Steering committee member & SIOP/WHO-GICC liaison
Co-Chair, SIOP Membership Committee (2022)
Member, Steering Committee of SIOP-PARC program (Program for Advancing Research Capacity in Pediatric Oncology)
Member, SIOP Committee for Education & Training
Lead for SIOP Global Mapping Project for Asia
SIOP Asia liaison: Rare Cancers ESMO-Asia & Asian Society for Oncofertility Member Ethics

Committee, Stem Cell Committee, King Edward Memorial Hospital, Mumbai

Board Member, Cherish Life India (Childhood Cancer NGO)

Founding Member InPOG (2010-15)

Member, Editorial Advisory Board, Pediatric Hematology Oncology Journal

Member, SIOP Governance Committee (2020-2021)

Chair, SIOP-PODC Committee on Training & Education (2010-2013)

SIOP-PODC Consultant (1994-2010)

Office Bearer SIOP Asia Board in various capacities: (2001-2013)

Past Chairperson, PHO Society, India* (2009-2012)

ICON* Ethics Committee Chairperson (2001-2003) & Member (2004-2016)

【Abstract】




APHOG Annual General Meeting 2024

Date: June 24th MON, 2024 17:00-18:00 JST
Venue: Yokohama Pacific, Room B On site only

Agenda

1. Opening message (2 min) Akira Nakagawara
2. Annual report 2023 (10 min) Godfrey Chan
3. Settlement of accounts 2023 (5 min) Purna Kurkure
Akira Nakagawara
4. Activities of SIOP Asia 2023 (7 min) Hiroki Hori
Muhammad Saghir Khan
5. WHO GICC related (5 min) Rashmi Dalvi
6. Global collaborative networking (5 min) Purna Kurkure
7. How to initiate clinical studies? (5 min) Chi-Kong Li
8. APHOG Annual Meeting 2024 (8 min) Akira Nakagawara
APHOG Prize Winner -> Select one person.
9. Election Committee (5 min) Godfrey Chan
10. Plan for 2024 (5 min) Godfrey Chan
11. Closing remark (2 min) Bharat Agarwal

This image shows a blank sheet of white paper with horizontal ruling lines. The lines are evenly spaced and extend across the width of the page. The paper has rounded corners and a thin black border. There are 20 horizontal lines in total, creating 19 rows for writing.



APHOG Annual Meeting 2024

16th Congress of Asia continental branch of
International Society of Pediatric Oncology

